Abstract
Aims
To investigate the effect of dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME).
Methods
Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled. Patients underwent a comprehensive ocular examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best-corrected visual acuity (BCVA), intraocular pressure, optical coherence tomography, ultra-widefield (UWF) retinography and UWF fluorescein angiography (UWFA).
Results
Nine eyes of seven consecutive patients (five males; mean age 66.4 ± 6.7 years) were enrolled. Mean duration of DR was 12.3 ± 8.4 years. Mean interval between UWFA acquisitions was 12.1 ± 2.1 weeks, and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Mean pre- and post-injection BCVA was 0.30 ± 0.20 and 0.21 ± 0.14 logMAR (p = 0.06), respectively. Mean pre- and post-injection central macular thickness was 449.8 ± 92.5 and 356.3 ± 52.4 μm (p = 0.03), respectively. Mean pre- and post-injection ischemic index was 24.0 ± 25.0 and 9.8 ± 12.1% (p = 0.0427), respectively.
Conclusions
Intravitreal dexamethasone implant reduces peripheral retina ischemia in patients with DR.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Diabetic retinopathy (DR) is the most common complication of diabetes mellitus (DM) and is a threatening cause of legal blindness among working-age people worldwide. The risk of developing significant visual impairment due to DR may be reduced with adequate control of systemic disease and prompt treatment of retinal complications [1].
Diabetic macular edema (DME) is a major cause of vision loss in patients with DR and may occur at any stage of diabetes. Retinal ischemia and microvascular changes are frequent complications of DR. Areas of capillary nonperfusion are clearly visualized with fluorescein angiography (FA); under optimal conditions, traditional FA can capture approximately 30° of the retina at once [2]. More than 25 years ago, the Early Treatment of Diabetic Retinopathy Study (ETDRS) developed the seven-standard fields (7SF) protocol in which seven areas of the retina obtained in different phases of retinal angiography were combined to give 75° visualization [3]. This technique makes difficult to evaluate capillary nonperfusion because of changing vascular fluorescence, imprecise field overlap and extravascular leakage of the fluorescein dye in the late phases of angiography [4].
The advent of ultra-widefield fluorescein angiography (UWFA) has provided the opportunity to capture a single high-resolution 200° retinal field, covering 82% of the retinal surface, where all vessels are in the same angiographic phase, allowing visualization of both central and peripheral retina. The ability to obtain full-field angiographic data in a single frame allows the ready visualization of peripheral nonperfusion and vascular leakage. This rapid acquisition system also requires less photographic expertise and less patient cooperation providing additional information about the severity of DR compared to traditional FA giving significant contribution to the management of diabetic patients.
Although UWFA has been extensively studied as a diagnostic tool, it may also have a role on DR treatment. Research results [5] have shown the important role of vascular endothelial growth factor (VEGF) in the pathogenesis of DR; retinal ischemia stimulates the production of VEGF, which can lead to the breakdown of blood–retinal barriers and may cause DME through an increase in vascular permeability in the macula. Anti-VEGF intravitreal injections have proven efficacy in suppressing VEGF load and improve DME. Moreover, Campochiaro et al. [6] reported that monthly injections of ranibizumab in patients with DME suppress VEGF load and consequently slow progression of retinal nonperfusion. A randomized clinical trial [7] by the Diabetic Retinopathy Clinical Research Network (DRCR.net) determined that 4 mg of intravitreal triamcinolone acetonide can reduce the risk of progression of diabetic retinopathy through 3 years. Lower rate of worsening in diabetic retinopathy severity may prevent development of retinal ischemia.
To the best of our knowledge, there is no evidence of dexamethasone intravitreal implant (Ozurdex™, DEX Implant) efficacy in reducing retinal nonperfusion in patients with DR. DEX implant demonstrated efficacy in the treatment of DME and has showed a favorable safety profile [8]. Therefore, secondary analyses of clinical trials have shown that suppression of VEGF slows progression of retinal nonperfusion in patients with DME, and it is uncertain as to whether DEX implant would have the same ameliorative effect on retinal ischemia. This analysis was designed to evaluate this potential effect by means of UWFA.
Materials and methods
A prospective interventional case series was carried out including nine eyes of seven patients with diagnosis of DME that presented at the Medical Retina and Imaging Unit of the Department of Ophthalmology, University Vita-Salute, San Raffaele Hospital in Milan and Bietti Foundation, IRCCS, in Rome, between October 2015 and March 2017. This study adhered to the tenets of the Declaration of Helsinki. All patients signed a written general consent to participate to studies, which was approved by the ethics committee of San Raffaele Hospital.
The inclusion criteria were: (1) patients 18 years of age or older with diabetes mellitus (type 1 or 2), (2) diagnosis of nonproliferative DR, (3) decreased vision from DME, (4) central macular thickness (CMT) ≥ 275 μm. The exclusion criteria were: (1) ocular comorbidities such as retinal arterial or venous occlusion, age-related macular degeneration, inherited macular disease and posterior segment inflammation, (2) any previous treatment (e.g., laser photocoagulation, photodynamic therapy, intravitreal injections of anti-VEGF or steroids), (3) presence of significant media opacities (e.g., cataract or corneal opacity).
All patients underwent a complete ophthalmologic examination at baseline (<2 weeks before treatment) and 10 ± 2 weeks after DEX Implant, including best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, slit-lamp biomicroscopy, lens status examination, intraocular pressure, indirect fundus ophthalmoscopy, structural spectral domain optical coherence tomography (SD-OCT), ultra-widefield color fundus images and UWFA. Optical coherence tomography examinations were performed using Spectralis (Heidelberg Engineering, Heidelberg, Germany). The structural SD-OCT minimum acquisition protocol included 19 horizontal raster linear B-scans, each composed by nine averaged OCT B-scans (1024 A-scans per line) at 240 µm intervals, covering an area of 20 degrees by 15 degrees. CMT in the central 1-mm-diameter circle of the ETDRS thickness map was recorded with the Spectralis Software (Heidelberg Eye Explorer, version 1.9.11.0, Heidelberg Engineering, Germany). Ultra-widefield color fundus images and UWFA were performed using the Optos California (Optos, PLC, Dunfermline, Scotland). This device combines both an ellipsoid mirror and a scanning laser ophthalmoscope to obtain panoramic fundus images up to the ora serrata. After standard intravenous infusion of 5 cc of sodium fluorescein 10%, UWFA images were obtained during the early (45 s), middle (2 min and 39 s) and late (5 min) phases of the angiography. In addition to a central image centered on the macula, the FA images were steered superiorly, temporally, nasally and inferiorly to allow clear visualization of the peripheral edge of the visible retinal vasculature. Peripheral retinal ischemia in all eyes included in the analyses was quantified by ischemic index (ISI) at UWFA baseline and 10 ± 2 weeks after intravitreal DEX implant (this timeline period was chosen on the basis of the pharmacodynamic of the drug) [9]. In order to quantify capillary nonperfusion, a single operator (AR) calculated ISI on early macula-centered UWFA frames, as described elsewhere [10,11,12]. Briefly, images were exported in Joint Photographic Experts Group (jpeg) format with no change in contrast, gamma or brightness and imported on ImageJ software (National Institutes of Health, Bethesda, Maryland, USA). Total retinal surface and nonperfused areas were manually outlined, and ISI was calculated as the ratio between ischemic retina and total retinal area. DR grading was performed on ultra-widefield color fundus images using the severity scale proposed by Wilkinson and colleagues [13].
Prism 6.0 software (GraphPad Software, San Diego, CA) was used to analyze the data. Results of descriptive analyses were expressed as means ± standard deviations for quantitative variables and as counts and percentages for categorical variables.
Results
The UWFA images of nine eyes from seven consecutive patients (five males; mean age 66.4 ± 6.7 years) with type 2 DM were evaluated at baseline and 10 weeks after intravitreal dexamethasone implant. All patients were in good control of systemic metabolism. Two patients had DME in both eyes, and one fellow eye was excluded because of previous macular laser treatment. The mean duration of DR was 12.3 ± 8.4 years. The mean interval between the UWFA acquisition was 12.1 ± 2.1 weeks, and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Table 1 shows demographics of the patients included.
Mean BCVA at baseline was 0.30 ± 0.20 logMAR and improved to 0.21 ± 0.14 logMAR at 10-week follow-up (p = 0.06). The mean baseline CMT was 449.8 ± 92.5 μm, which reduced to 356.3 ± 52.4 μm 10 weeks following intravitreal injection (p = 0.03).
The mean ISI as evaluated on UWFA at baseline was 24.0 ± 25.0% and reduced to 9.8 ± 12.1% at 10-week follow-up (2.4-fold mean reduction, p = 0.0427). Figure 1 shows UWFA images of peripheral ISI before and after intravitreal dexamethasone implant in patient #2. Patient #2 also improved DR grade from severe to moderate after intravitreal DEX implant. Table 2 shows main clinical findings of the patients included in the study. One patient developed intraocular pressure (IOP) rising to 32 mmHg after DEX implant which normalized to 19 mmHg with application of topical dorzolamide/timolol fixed combination (Cosopt™) bid.
Discussion
In this pilot study, DEX implant provided reduction in peripheral retinal nonperfusion and improvement in vision and macular edema in patients with DR. Overall, the findings of the current study confirm the role of UWFA in assessing the DR extension and retinal changes associated with DME, which may be definitely considered as a valuable tool for identifying peripheral nonperfusion. Several studies in diabetic eyes have already demonstrated greater detection, compared to conventional FA, in visualizing peripheral retinal ischemia in DR.
Detection and delineation of retinal vascular nonperfusion in the retinal periphery may be of clinical value. Wessel et al. [12] reported a significant correlation between diabetic macular edema and peripheral retinal ischemia evaluated by UWFA. Moreover, Patel et al. [10] found a correlation between recalcitrant DME with larger areas of retinal nonperfusion in UWFA and greater severity of DR. Sim et al. [14] investigated the association between peripheral retinal ischemia in UWFA images and central ischemia in DR. They observed a positive correlation between these two variables indicating how both conditions share a common pathogenesis, such as capillary nonperfusion. This pilot study demonstrates the feasibility of quantifying retinal nonperfusion treatment response by means of ISI; moreover, DEX implant resulted effective not only in reducing breakdown of the blood–retinal barrier but also in improving ISI in all patients included (2.4-fold mean reduction).
In patients with DME, the neutralization of intraocular VEGF levels by anti-VEGF improves macular edema and reverses the worsening in retinal nonperfusion. [6].
Similarly, corticosteroids can reduce the risk of progression of diabetic retinopathy through 3 years [7]. In fact, corticosteroids have been shown to down-regulate VEGF production and to reduce a large number of vasoactive factors [15, 16]. There are some patients in whom intravitreal anti-VEGF injections are not sufficient to reduce DME and this suggests there are other pro-permeability factors in addition to VEGF that play a role in patients with DME [17]. Lower rate of worsening in diabetic retinopathy severity may prevent development of retinal ischemia.
The obvious limitation of this study is the small sample size given its pilot design, and further studies with larger number of patients are needed to confirm our preliminary findings. Moreover, ISI quantification was carried out by one single operator and this could represent another study limitation. The present study should be considered as a starting point to promote prospective clinical trials in order to better analyze the effect of DEX implant on recovering retinal nonperfusion and avoiding worsening of DR progression in patients with DME.
References
Wessel MM, Nair N, Aaker GD, Ehrlich JR, D’Amico DJ, Kiss S (2012) Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol 96(5):694–698. doi:10.1136/bjophthalmol-2011-300774
Witmer MT, Kiss S (2013) Wide-field imaging of the retina. Surv Ophthalmol 58(2):143–154. doi:10.1016/j.survophthal.2012.07.003
Diabetic retinopathy study (1981) Report number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy. Invest Ophthalmol Vis Sci 21(2):1–226
Soliman AZ, Silva PS, Aiello LP, Sun JK (2012) Ultra-wide field retinal imaging in detection, classification, and management of diabetic retinopathy. Semin Ophthalmol 27(5–6):221–227. doi:10.3109/08820538.2012.708812
Nguyen QD, Brown DM, Marcus DM et al (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801. doi:10.1016/j.ophtha.2011.12.039
Campochiaro PA, Wykoff CC, Shapiro H, Rubio RG, Ehrlich JS (2014) Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 121(9):1783–1789. doi:10.1016/j.ophtha.2014.03.021
Bressler NM, Edwards AR, Beck RW et al (2009) Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 127(12):1566–1571. doi:10.1001/archophthalmol.2009.308
Malcles A, Dot C, Voirin N et al (2016) Real-life study in diabetic macular edema treated with dexamethasone implant: the reldex study. Retina. doi:10.1097/IAE.0000000000001234
Haller JA, Bandello F, Belfort R Jr et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12):2453–2460
Patel RD, Messner LV, Teitelbaum B, Michel KA, Hariprasad SM (2013) Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol 155(6):1038–1044 e1032. doi:10.1016/j.ajo.2013.01.007
Tan CS, Sadda SR, Hariprasad SM (2014) Ultra-widefield retinal imaging in the management of diabetic eye diseases. Ophthalmic Surg Lasers Imaging Retina 45(5):363–366. doi:10.3928/23258160-20140909-07
Wessel MM, Aaker GD, Parlitsis G, Cho M, D’Amico DJ, Kiss S (2012) Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy. Retina 32(4):785–791. doi:10.1097/IAE.0b013e3182278b64
Wilkinson CP, Ferris FL 3rd, Klein RE et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682. doi:10.1016/S0161-6420(03)00475-5
Sim DA, Keane PA, Rajendram R et al (2014) Patterns of peripheral retinal and central macula ischemia in diabetic retinopathy as evaluated by ultra-widefield fluorescein angiography. Am J Ophthalmol 158(1):144–153 e141. doi:10.1016/j.ajo.2014.03.009
Edelman JL, Lutz D, Castro MR (2005) Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80(2):249–258. doi:10.1016/j.exer.2004.09.013
Tamura H, Miyamoto K, Kiryu J et al (2005) Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46(4):1440–1444. doi:10.1167/iovs.04-0905
Dugel PU, Bandello F, Loewenstein A (2015) Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 9:1321–1335. doi:10.2147/OPTH.S79948
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Lea Querques, Alessandro Rabiolo, Maria Cristina Parravano, Riccardo Sacconi declare that they have no conflict of interest. Francesco Bandello consultant for: Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bayer Shering-Pharma (Berlin, Germany), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), NovagaliPharma (Évry, France), Novartis (Basel, Switzerland), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA). Giuseppe Querques consultant for: Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Heidelberg (Germany), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Zeiss (Dublin, USA).
Ethical standard
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Human and animal rights
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008.
Informed consent
Informed consent was obtained from all patients for being included in the study.
Additional information
Managed by Antonio Secchi.
Rights and permissions
About this article
Cite this article
Querques, L., Parravano, M., Sacconi, R. et al. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study. Acta Diabetol 54, 769–773 (2017). https://doi.org/10.1007/s00592-017-1010-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-017-1010-1